Effect of serum vitamin d in HBA1c articles
Reading File
Searching PubMed
"vitamin D" AND "HbA1c" AND diabetes
Reading Article
PMID: 39355942
Reading Article
PMID: 36647067
Reading Article
PMID: 41010515
Reading Article
PMID: 34960022
Finding Sources
Here is a comprehensive summary of the current evidence on the effect of serum vitamin D on HbA1c:
Effect of Serum Vitamin D on HbA1c: Evidence Summary
Quick Overview
There is now strong, consistent evidence from multiple meta-analyses that vitamin D supplementation significantly reduces HbA1c in patients with type 2 diabetes (T2D) and prediabetes. The reduction is modest but clinically meaningful, particularly in vitamin D-deficient individuals receiving high-dose, short-duration supplementation.
Key Meta-Analyses and Systematic Reviews
1. Chen et al., 2024 - Diabetes, Obesity & Metabolism (39 RCTs, n=2,982)
PMID 39355942 - The most updated and comprehensive meta-analysis to date:
- HbA1c reduction: WMD -0.30% (95% CI: -0.43 to -0.18) - statistically significant
- Also reduced FBG (WMD -0.49 mmol/L), HOMA-IR (WMD -0.39), and fasting insulin (WMD -1.31 µIU/mL)
- Key subgroup findings:
- Effect was greater in patients with baseline HbA1c ≥ 8%
- Short-term, high-dose supplementation was more effective
- Vitamin D-deficient patients and overweight patients showed greater benefit
- Conclusion: Vitamin D supplements can be recommended as a complementary treatment for T2D
2. Farahmand et al., 2023 - BMC Endocrine Disorders (46 RCTs, n=4,313)
- HbA1c reduction: WMD -0.20% (95% CI: -0.29 to -0.11), p<0.001
- Also significantly reduced FPG (WMD -5.02 mg/dL) and HOMA-IR (WMD -0.42)
- Greatest effect with higher doses, shorter intervention periods, and deficient baseline vitamin D
- Note: substantial heterogeneity between studies and possible publication bias acknowledged
3. Bruna-Mejias et al., 2025 - Nutrients (20 studies, multiple diabetes types)
- Vitamin D supplementation significantly reduced HbA1c, HOMA-IR, LDL cholesterol, total cholesterol, triglycerides, fasting insulin, fasting glucose, and C-reactive protein
- Also increased rate of normoglycemia reversion in prediabetics
- Beneficial effects seen across type 1, type 2, and prediabetes
4. Zhang et al., 2021 - Nutrients (Prediabetes focus, 29 RCTs, n=3,792)
- HbA1c reduction: SMD -0.14 (95% CI: -0.22 to -0.06) in prediabetes
- Also improved FBG (SMD -0.38) and fasting insulin
- Subgroup: Long-term supplementation (≥1 year) improved HOMA-IR and HOMA-B
- Patients with baseline 25(OH)D < 50 nmol/L showed greater benefit for 2h-PG
Proposed Mechanisms Linking Vitamin D to HbA1c
| Mechanism | Detail |
|---|---|
| Insulin secretion | Vitamin D receptors (VDR) on pancreatic beta cells; vitamin D activates insulin gene transcription |
| Insulin sensitivity | Reduces systemic inflammation (lowers TNF-α, IL-6); improves peripheral glucose uptake |
| HOMA-IR | Consistent reductions in insulin resistance across studies |
| Beta-cell function | Vitamin D may protect beta cells from apoptosis; improves HOMA-B |
| Adipose tissue | VDR in adipocytes; vitamin D modulates adipokine secretion affecting glucose metabolism |
Factors Modifying the Vitamin D - HbA1c Effect
| Factor | Direction of Effect |
|---|---|
| Baseline vitamin D deficiency (25-OH-D < 50 nmol/L) | Larger HbA1c reduction |
| High-dose supplementation | Greater benefit |
| Shorter duration (more intensive) | More pronounced glycemic effect |
| Higher baseline HbA1c (≥8%) | Greater absolute reduction |
| Overweight/obese patients | More benefit than normal weight |
| Asian populations | May show greater 2h-PG and HbA1c improvements |
Clinical Interpretation
- The average HbA1c reduction with vitamin D supplementation is approximately -0.2% to -0.3% in T2D patients - comparable in magnitude to some lifestyle interventions
- This is on top of standard antidiabetic therapy
- Effect is most pronounced in patients who are vitamin D deficient at baseline
- Vitamin D supplementation is not a substitute for standard diabetes therapy but may serve as a useful adjunct, particularly in deficient patients
- Baseline 25(OH)D testing before supplementation is advisable to identify who is most likely to benefit
Notable Limitations Across the Literature
- High heterogeneity between trials (different doses, durations, populations, formulations)
- Many trials are short-term (< 6 months)
- Some evidence of publication bias in the field
- Optimal dose and duration remain undefined
Summary of Key PMIDs for Citation:
- Chen 2024 (39 RCTs, T2D): PMID 39355942
- Farahmand 2023 (46 RCTs, T2D): PMID 36647067
- Bruna-Mejias 2025 (multi-diabetes types): PMID 41010515
- Zhang 2021 (prediabetes): PMID 34960022
This is a shared conversation. Sign in to Orris to start your own chat.